Simpson Thacher represented the underwriters, led by Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC, in connection with a registered offering of $4 billion in notes by Pfizer Inc. (“Pfizer”).
The notes were issued in four series with maturities ranging from 2025 to 2050, with proceeds intended to be used for general corporate purposes, including to repay a portion of the company’s outstanding commercial paper and to refinance, redeem or repurchase existing debt.
Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines.
The Simpson Thacher team included Joe Kaufman, Jonathan Ozner and Ki Hoon Kim (Capital Markets); Jon Cantor and Brian Mendick (Tax); Genevieve Dorment (Intellectual Property); Jamin Koslowe (Executive Compensation and Employee Benefits); Adeeb Fadil and Noreen Lavan (Environmental); and Jennie Getsin (FINRA and Blue Sky).